TARMAC study overview and outcomes. (A) Patients in the phase 2 TARMAC study started ibrutinib, 560 mg daily, at least 7 days before apheresis for CTL019 and continued through lymphodepletion (LD), CAR T-cell infusion, and at least 6 months after infusion. Patients who achieved MRD-negative CR (as detected by flow cytometry) stopped ibrutinib, whereas patients with detectable disease continued until progression or unacceptable toxicity. (B) Mantle cell disease outcomes are shown across patients in the trial by Lugano criteria and by peripheral blood and marrow MRD, as detected by flow cytometry or ClonoSEQ (molecular [Mol]). PD, progression of disease. Professional illustration by Patrick Lane, ScEYEnce Studios.